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Abstract
Background: With the incidence of breast cancer rising worldwide, we are evaluating the iBreastExam (iBE) (UE
LifeSciences Inc.), a handheld breast scanning device that can be utilized by community health workers to screen
for breast abnormalities. The purpose of this study is to determine the sensitivity of the iBE in a population
undergoing diagnostic breast imaging.
Methods: Adult patients presenting to a breast imaging center for a diagnostic workup were eligible. Patients
underwent an iBE exam performed by a trained ultrasound technician followed by their indicated imaging.
Demographic, imaging, and biopsy data were recorded.
Results: Seventy-eight iBE exams were completed, 77 females and one male with a mean age of 42 (21–79). All
patients were evaluated by ultrasound, 52 had diagnostic mammography and 39 had biopsies. Imaging and/or
biopsy confirmed a mass (fibroadenoma, cyst, papilloma, myofibroblastoma, fat necrosis, DCIS, or cancer) in 60
patients. Twelve patients had a cancer diagnosed. In total, 342 quadrants were scanned, 77 quadrants had lesions
confirmed on imaging, and iBE correctly identified 66 lesions for a sensitivity of 86 % and specificity of 89 %.
Conclusions: This validation study demonstrated excellent sensitivity of iBE for the identification of clinically
significant lesions in patients presenting for diagnostic imaging.
Trial registration: A Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation
Study: NCT02814292.
Background
The incidence of breast cancer is rising rapidly world-
wide. Since 2008, the incidence of breast cancer has
increased by more than 20 % worldwide [1]. Globally,
breast cancer now represents one in four of all cancers
among women. Early detection improves the survival
rate, makes treatment less costly, and lowers the overall
burden of the disease. The iBreastExam (iBE) device was
developed as a pre-screening tool that could identify
women in need of further breast imaging without re-
quiring extensive breast screening infrastructure. This
inexpensive handheld device uses piezoelectric palpation
to enhance the clinical breast exam (CBE) for detection
of breast masses that require further investigation.
The iBE device was built on the principle of the
piezoelectric finger (PEF) detector. After their initial
development, the PEF was proven in bench-top work
on breast phantoms and subsequently in excised hu-
man tumors with excellent detection ability and size
prediction [2]. A pilot in vivo clinical trial was then
completed using a very basic array of four PEFs with
excellent detection of breast lesions in women un-
dergoing clinical evaluation [3]. Subsequently, the iBE
device was developed as a 16 finger array with a rapid
wireless mobile processor algorithm and durable bat-
tery powered handpiece. The device was developed to
be operated by a technician or health care worker and
does not require a radiologist for interpretation. This
prospective study was designed specifically to validate
the ability of the iBE device to detect breast abnormal-
ities worthy of further diagnostic imaging.
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Approval was obtained from the University of Pennsylvania
Institutional Review Board (IRB, protocol # 819121) and
the Abramson Cancer Center Clinical Trials Scientific Re-
view Committee (CTSRMC, UPCC # 33113) for this study.
All patients signed informed consent prior to participation.
Eighty-nine patients with suspected breast lesions were
consented and examined with the iBE device from August
2014 through January 2015. Patients participated for one
clinic visit during which the iBE device was used to exam-
ine the areas of concern as well as uninvolved areas of the
breast. Eleven patients were excluded from the analysis
due to missing the iBE data. Missing iBE data was a result
of incomplete data transfer from the iBE. If the wireless
communication of the device was incomplete, repeat
scans were not attempted due to time constraints of the
high volume at the breast imaging center. Results from
the iBE did not influence or change the medical care given
to the patients.
Women and men 18 years of age or older with symp-
tomatic breast masses or women with asymptomatic
breast masses discovered by palpation or imaging were
included. Patients under 18 years of age were excluded.
The current pathway of breast lesion screening and
detection at this institution begins with a screening ma-
mmogram in asymptomatic women. In women with a
negative screening mammogram, the pathway is complete
and a regular interval follow-up is recommended. This
tends to be the case even in women with dense breast
tissue. In women with an abnormal screening mammo-
gram or palpable masses from clinical breast exam, a diag-
nostic mammogram is done in women over 40 and an
ultrasound in all women. Typically, if a woman is under
35 with a palpable mass, mammography is skipped and
ultrasound is the diagnostic test of choice. If the additional
imaging reveals something suspicious, a biopsy may be
recommended for confirmation. Since the inclusion cri-
teria required the participating patients to have a mass
detected by palpation or imaging, the majority of the
patients were recommended for further imaging. All
follow-up diagnostic information was extracted from the
electronic medical record and recorded. The type and
number of diagnostic techniques were determined by the
radiologist and/or the surgical oncologist based on the
results of the previous exams, not including the iBE.
Classification
Initially in this study, a positive or a negative finding was
defined only by the Breast Imaging-Reporting and Data
System (BIRADS) classification assigned by the radiologist
interpreting the results of the diagnostic technique(s).
BIRADS 1 and 2 defined a negative detection while
BIRADS 0, 3, 4, 5, and 6 defined a positive detection
or clinically relevant finding. However, it was discovered
that many of the radiology reports classified as BIRADS 1
or 2 reported a measurable finding such as a cyst. Since the
iBE was designed to be a pre-screening tool with the intent
to identify all lesions, not just cancerous lesions, the posi-
tive/negative classification for this study was revised to
include the presence or absence of clinically relevant de-
tectable lesions as follows: negative findings included nega-
tive study, fibrocystic changes, benign calcification, and
gynecomastia while positive findings included fibroaden-
oma, cyst, myofibroblastoma, fat necrosis, papilloma, ductal
carcinoma in situ (DCIS), or cancer. Thus, when analyzing
the iBE results by independent quadrants, each iBE quad-
rant was compared to the correlating quadrant of a mam-
mography, ultrasound, biopsy, or MRI. A positive finding
was defined as the presence of a measurable finding in that
quadrant independent of BIRADS classification.
Device
The iBreastExam™ or iBE™ (Fig. 1a, b) consists of a hand-
held compression probe containing a 4 × 4 array of
piezoelectric tactile pressure sensors, a custom built
electronic board and a tablet. The iBE communicates
wirelessly with a mobile device to display and store the
findings in real time. Compression data are recorded as
a unique file at the end of every scan to the mobile
device which is synced to an encrypted database via
Dropbox where a copy is saved. No identifiable data are
collected or stored by the iBE software.
The iBE evaluations were performed by an ultrasound
technologist who was trained to use the iBE by the
manufacturer and the principal investigator of the study.
Training involved 1 h of education about the functions
of the device, practice on a breast phantom, and then 10
observed iBE studies with the principal investigator. The
results of the iBE were displayed on the touch screen in
a pressure map fashion (Fig. 1c, d). Green indicates
normal breast tissue while red indicates a lesion was
detected meaning the iBE is suggesting further testing to
characterize the lesion, as the iBE does not differentiate
the type of lesion it detects. The patient lies in the
supine position while the test was done. The device was
calibrated on the breast in an uninvolved area; it can be
recalibrated multiple times. The iBE records the data
and collects into 4 × 4 array map of the breast, and each
individual square represents the 4 × 4 array of the PEFS.
This map was divided into sectors demarcated by three
consecutive hours of a clock in order to directly com-
pare to the clock positioning assigned by mammography
or ultrasonography.
Results
The mean age of the patients was 42 years old (age
range 21 to 79 years). The racial distribution of the
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patient population was 51 % Caucasian, 35 % African
American, 3 % Asian, 5 % Hispanic, and 6 % Unknown.
One male participated in the study. All 78 patients
underwent ultrasonography while only 52 underwent
mammography and 39 underwent biopsies (50 %).
The iBE results were evaluated by definitive quadrants.
The definitive quadrants break down the superimposed
clock into four equal sectors (e.g., 12–3, 3–6, 6–9, 9–
12). The quadrants were defined when the iBE identified
a positive finding; the positive finding became the center
of a quadrant, meaning if a positive finding was identi-
fied at 5:00, the first quadrant would be 3:30–6:30 and
the remaining quadrants defined as follows 6:30–9:30,
9:30–12:30, and 12:30–3:30.
Through imaging, 77 of the quadrants were deter-
mined as a positive detection and 265 as negative find-
ings with an overall total of 342 quadrants evaluated by
the iBE (Table 1). Out of the 77 positive quadrants, 66
were identified correctly (true positive) by the iBE result-
ing in a Sn = 85.7 %, and 237 out of 265 quadrants were
correctly characterized normal (true negative) resulting
in Sp = 89.4 %. Also, illustrated in Table 1 are the
positive detection rate, negative detection rate, and
accuracy, positive predictive value (PPV) = 70.2 %,
negative predictive value (NPV) = 95.6 %, and accuracy
(Acc) = 88.6 %, respectively.
Table 2 demonstrates the distribution of BIRADS
categories according to the patient’s final report of the
evaluation of the entire breast. BIRADS (1 and 2) were
assigned to 30 patients, and BIRADS (3, 4, 5, and 6) were
assigned to 48 patients. A total of 5 masses went undetected
by the iBE, all of which were under 1 cm in size. Of the false
negatives, 3 false negatives were classified as BIRADS 3,
noncancerous findings while the remaining 2 were can-
cerous and classified as BIRADS 4 until biopsies were com-
pleted. Two of the 3 noncancerous false negatives were
fibroadenomas, and the remaining 1 was stromal calcifi-
cation. One cancerous false negative was retroareolar 0.5-
cm ductal carcinoma in situ, and the second was 0.7-cm
mucinous carcinoma located at 8:30, 6 cm from the nipple.
Fig. 1 a iBE device and the device in use. b The 4 × 4 array of PEFS. c Data pressure map illustration of normal or negative results. d Data
pressure map illustration of abnormal or positive results
Table 1 iBE accuracy measures by definitive quadrants
Total definitive






Test positive quadrant 66 28 PPV = 70.2 %
Test negative quadrant 11 237 NPV = 95.6 %
Measures Sn = 85.7 % Sp = 89.4 % Accuracy = 88.6 %
Table 2 Distribution of BIRADS and number of FN in each category
BIRADS Final report No. of FN
1 3 (4 %) 0
2 27 (35 %) 0
3 26 (33 %) 3
4 13 (16.7 %) 2
5 1 (1.3 %) 0
6 8 (10 %) 0
Total 78 5
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Malignancy
Of the 78 patients, 12 patients were found to have a
malignancy. Ten of the 12 cancerous diagnoses were
detected by the iBE (Sn = 83 %, Sp = 74.5 %) while 2
were undetected (Table 3). The size of malignancies
detected ranged from of 0.9 to 3.8 cm with a mean size
of 1.91 cm ± 0.9. The two undetected by the iBE mean
size was 0.6 ± 0.1 cm. One of the undetected malignan-
cies was ductal carcinoma in situ; the other was mucin-
ous carcinoma. Out of the 10 malignant masses detected
by the iBE, 6 were invasive ductal carcinoma, 2 were
invasive mammary carcinoma and 1 was ductal carcin-
oma in situ. Two of the detected masses were located in
the retroareolar region.
Diagnostic mammograms were performed on 11 of
the 12 cancers diagnosed, while one patient had a diag-
nostic ultrasound only (Table 4). Ten of the 11 cancers
were detected by mammogram (Sn = 91 %, Sp = 51 %)
and one undetected, a 1-cm size invasive ductal carcin-
oma. The iBE detected the cancer the mammography
missed; conversely, mammography identified the cancers
the iBE missed.
Tables 3 and 4 display the accuracy of malignancy de-
tection of the iBE evaluation and mammography. Table 4
shows the diagnostic mammogram with a total of 32
positive findings. Positive findings for mammograms
were defined by the radiologist assigned BIRADS 0, 4, 5,
and 6, and negative evaluations were defined as BIRADS
1, 2, and 3. BIRADS 3 is added to the negative evalu-
ation, because BIRADS 3 is considered nonmalignant
category. All but one of the BIRADS 0 was eventually
determined to be a BIRADS 4 by ultrasound or biopsy.
The positive predictive value, negative predictive value,
and the accuracy of the mammogram to detect cancer
were determined to be 33.3, 95.5, and 59.6 %, respect-
ively. The positive predictive value, negative predictive
value, and the accuracy of the iBE to detect cancer were
determined to be 10.6, 99, and 74.9 %, respectively.
Discussion
The iBE demonstrated acceptable sensitivity and spe-
cificity in this cohort of patients requiring diagnostic
imaging for palpable lesions or abnormal screening
mammograms. This study was designed to validate the
iBE’s ability to detect lesions in patients with a positive
breast exam or imaging.
Mammography and ultrasonography demonstrate sensi-
tivity rates of 85–88 % [4–7] and 93–97 % [7–10] for a
general screening and diagnostic population, while the iBE
in this population of known detectable findings demon-
strated a comparable sensitivity of 85.7 %. The perform-
ance of this device meets the threshold of a pre-screening
device when compared to the current pre-screening tool,
CBE, which has a sensitivity of 50–60 % [11, 12].
The iBE detected all but two of the malignancies, both
of which were less than a 1 cm in size. This threshold is
an important one for a pre-screening device in low-
resource settings. The goal of early detection is to identify
malignancies where intervention will improve survival,
possibly with reduced need for expensive and morbid
adjuvant therapy. Identifying cancers in stages I and II
before they become stages III or IV definitely fulfills this
criterion in a low-resource environment [13–16]. The iBE
is designed to be a pre-screener in order to help identify
masses that need to be investigated further; therefore, this
amplified sensitivity could be valued to detect potentially
significant underlying masses.
Directly comparing the sensitivity of cancer detection
demonstrates that both the iBE (83 %) and mammography
(91 %) are reliable tools to identify patients with cancer
(Tables 3 and 4). While the sensitivity of cancer detection
is lower, the specificity of the iBE (74 %) surpasses that of
mammography (51 %) indicating that the iBE is superior
to mammography at not falsely identifying patients with
cancer suggesting that the iBE as a pre-screening tool will
be less likely to cause unnecessary stress and anxiety.
Reexamining the iBE results to reflect a patient outcome
instead of a single breast or a portion of the breast, we de-
termined that 61 of the 78 patients required a mammogram
or an ultrasound for further evaluation of the screening re-
sults. Of those 61 patients, 56 (91.8 %) were properly rec-
ommended by the iBE for a mammogram or ultrasound;
however, 5 (8.2 %) were missed by the iBE that needed a
mammogram or ultrasound for further information. Based
on the imaging results, 17 patients did not require a mam-
mogram or ultrasound, 4 (23.5 %) of them were identified
correctly by the iBE while 13 (76.5 %) were not.
All 78 patients were eligible to participate in this study
due to positive imaging, clinical breast exam, or a self-
breast exam identifying a suspicious area directing them
down the diagnostic pathway, resulting in a 50 % biopsy
rate for this study population. This incidental high
Table 3 iBE accuracy for malignancy detection
No cancer Cancer Total
IBE (+) 84 10 94
IBE (−) 246 2 248
Total 330 12 342
Measures Sn = 83 % Sp = 74.5 %
Table 4 Mammogram accuracy for malignancy detection
No cancer Cancer Total
Mammogram (+) 20 10 32
Mammogram (−) 21 1 21
Total 41 11 52
Measure Sn = 91 % Sp = 51 %
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biopsy rate was beneficial because the biopsy results
confirmed the identity/classification of the suspicious
masses detected by the iBE or imaging. We demon-
strated the iBE’s ability to screen similar to mammog-
raphy in this cohort. The iBE screenings in this study
did not lead to an increase rate of biopsies as the iBE re-
sults did not influence the patient’s diagnostic pathway.
The high biopsy rate in this study was a result of exam-
ining a population on the diagnostic testing pathway.
The iBE is a sensitive tool that is ready for validation in
a large screening cohort. This screening study is already
underway, and we hope to have a reliable specificity value
from that trial before deploying this device in low-
resource settings around the world. Because the device is
portable, radiation free, and painless and does not require
a radiologist, the iBE is an excellent pre-screening device.
When used to select patients for further diagnostic
workup with mammogram, ultrasound, and/or biopsy, the
iBE has the potential to bring access to breast cancer
screening and diagnosis to women who currently have
little or no access to screening mammography worldwide.
We see the iBE as a potential powerful screening tool
for use in the third world countries with limited resources
where mammography and clinical breast exam by a
trained physician is not readily available. Positive findings
by the iBE could then allow for patients to be referred to
larger medical centers where ultrasound and mammog-
raphy may be available and, more importantly, where
surgical excision could be performed. Training lay people
on the use of the device could potentially provide screen-
ing to rural and underserved areas of undeveloped nations
where women historically have had no access to breast
cancer screening. The iBE device is currently being piloted
in a rural area in India where due to limited economic
resources, women have essentially no access to mam-
mography and present with late-stage breast cancers. As
described in the literature, late-stage breast cancers have
poorer prognosis than early stage breast cancers [16]. Due
to the significantly lower cost of the iBE compared to
conventional mammography, we see this device as a very
useful adjunct to breast cancer detection worldwide in
underdeveloped, third world nations with limited medical
economic resources and a need for improved breast
cancer screening. Indeed, a group in Bangalore, India, has
recently reported on the use of the iBE in a population of
women presenting for annual health exams [17]. Abnor-
mal iBE studies were followed by directed ultrasound or
mammography as confirmatory studies. In that popula-
tion, a sensitivity of 84 % and specificity of 94 % for the
detection of image detected breast lesions.
Conclusions
This validation study demonstrated excellent sensitivity
of iBE for the identification of clinically significant
lesions in patients presenting for diagnostic imaging.
The iBE demonstrates significant potential as a low-cost
screening tool in low-resource environments.
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